全文获取类型
收费全文 | 2339篇 |
免费 | 159篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 178篇 |
妇产科学 | 91篇 |
基础医学 | 219篇 |
口腔科学 | 44篇 |
临床医学 | 159篇 |
内科学 | 487篇 |
皮肤病学 | 45篇 |
神经病学 | 148篇 |
特种医学 | 127篇 |
外科学 | 274篇 |
综合类 | 70篇 |
一般理论 | 1篇 |
预防医学 | 94篇 |
眼科学 | 144篇 |
药学 | 129篇 |
中国医学 | 3篇 |
肿瘤学 | 250篇 |
出版年
2023年 | 17篇 |
2022年 | 20篇 |
2021年 | 58篇 |
2020年 | 25篇 |
2019年 | 48篇 |
2018年 | 77篇 |
2017年 | 55篇 |
2016年 | 61篇 |
2015年 | 59篇 |
2014年 | 104篇 |
2013年 | 78篇 |
2012年 | 131篇 |
2011年 | 154篇 |
2010年 | 87篇 |
2009年 | 73篇 |
2008年 | 107篇 |
2007年 | 114篇 |
2006年 | 108篇 |
2005年 | 83篇 |
2004年 | 65篇 |
2003年 | 79篇 |
2002年 | 83篇 |
2001年 | 61篇 |
2000年 | 73篇 |
1999年 | 72篇 |
1998年 | 28篇 |
1997年 | 18篇 |
1996年 | 24篇 |
1995年 | 17篇 |
1994年 | 21篇 |
1993年 | 18篇 |
1992年 | 35篇 |
1991年 | 45篇 |
1990年 | 33篇 |
1989年 | 35篇 |
1988年 | 27篇 |
1987年 | 33篇 |
1986年 | 14篇 |
1985年 | 24篇 |
1984年 | 13篇 |
1983年 | 18篇 |
1981年 | 15篇 |
1977年 | 16篇 |
1976年 | 16篇 |
1975年 | 15篇 |
1973年 | 13篇 |
1972年 | 16篇 |
1971年 | 12篇 |
1968年 | 15篇 |
1967年 | 12篇 |
排序方式: 共有2511条查询结果,搜索用时 15 毫秒
1.
Apoorva Challa Neeraj Mahajan Seema Sood Arti Kapil Bimal Kumar Das Vishnubhatla Sreenivas Somesh Gupta 《Indian journal of medical microbiology》2022,40(3):433-435
Treatment guidelines for management of uncomplicated gonorrhoeae have been recently modified owing to alarming upsurge in azithromycin resistance. This study investigated the prevalence and genetic determinants of gonococcal azithromycin resistance in India. Four (5.7%) of 70 gonococcal isolates were resistant to azithromycin. Of 16 isolates investigated for molecular mechanisms of resistance, 13 (81.3%) and 6 (37.5%) isolates exhibited mutations in coding and promoter regions of mtrR gene, respectively. However, ermA, ermB and ermC genes or mutations in rrl gene were absent in all isolates. Azithromycin resistance is low in India posing no immediate threat to use of dual-therapy for syndromic management. 相似文献
2.
3.
4.
5.
6.
7.
Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma 总被引:9,自引:3,他引:6
Weisenburger DD; Gordon BG; Vose JM; Bast MA; Chan WC; Greiner TC; Anderson JR; Sanger WG 《Blood》1996,87(9):3860-3868
Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a distinct clinicopathologic entity associated with the t(2;5) (p23;q35). However, the specificity of t(2;5) for ALCL has not been carefully studied. Therefore, we performed a detailed analysis of all cases of ALCL with abnormal cytogenetics results in the Nebraska Lymphoma Study Group registry, as well as all other cases of non-Hodgkin's lymphoma with t(2;5) in the registry. We found the t(2;5) in only five of 10 cases of ALCL, four of whom were young patients. However, we also found the t(2;5) in 11 other cases of nonanaplastic lymphoma, including eight children with typical peripheral T-cell lymphomas of various types. The t(2;5) was also found in three older adults with B-cell lymphomas of various types. Thus, the t(2;5) was not specific for CD30+ ALCL. However, t(2;5) may define a clinicopathologic entity in children and young adults characterized by variable morphologies with a T-cell or indeterminate phenotype, CD30-positivity, nodal disease with frequent extranodal involvement, advanced stage, and an excellent response to therapy, including bone marrow transplantation for relapsed disease. The clinical relevance of the t(2;5) in older patients requires further study. 相似文献
8.
Ajit Sood Vandana Midha Neena Sood Manu Bansal 《Indian journal of gastroenterology》2006,25(6):283-285
BACKGROUND: The treatment of hepatitis C virus (HCV)-related cirrhosis is difficult due to high frequency of adverse effects. We retrospectively reviewed the case records of patients with HCV cirrhosis to evaluate the efficacy and tolerability of pegylated (peg) interferon and ribavirin treatment in these patients. METHODS: Medical records of 28 patients with HCV-related compensated cirrhosis were reviewed. The treatment protocol was a combination therapy of peg interferon alfa-2b (1 microg/Kg/week) plus oral ribavirin (10-12 mg/Kg/day). Primary endpoint was sustained virological response, with additional endpoints of drug tolerance, clinical or biochemical worsening and death. RESULTS: End-of-treatment virlogic response was seen in 24 of 28 patients (85%) and sustained virologic response in 15 of 28 (53%) patients. Biochemical end-of-treatment response and sustained response were seen in 20 and 16 patients (71% and 57%), respectively. Treatment had to be stopped in 3 patients due to decompensation of liver status in two and drug intolerance in one, while dose modification was required in two patients. CONCLUSIONS: Combination therapy with peg interferon plus ribavirin seems effective in patients with liver cirrhosis. High relapse rate, poor biochemical recovery and possibility of decompensation are issues that need to be kept in mind. 相似文献
9.
10.